This is a working overview of lyophilized peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-02 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Ac-SDKP (Thymosin Beta 4 Fragment (1–4), Goralatide) is an endogenous tetrapeptide derivative that is the N-acetylated derivative of the fragment composed of amino acids 1-4 derived from cleavage of the N-terminus of the signalling factor thymosin beta-4 by the enzyme prolyl oligopeptidase. It is a selective inhibitor of haematopoietic cell proliferation and has antiinflammatory, anti-fibrotic, and pro-angiogenic properties, with particular applications in preventing the development of kidney fibrosis and cardiac fibrosis following injury to these organs. Adamax BPC-157 CJC-1295 KPV tripeptide TB-500
In Ethiopia, the Civil Aviation Accident Prevention and Investigation Bureau of the Ethiopian Civil Aviation Authority (ECAA), which is an agency of the Ministry of Transport and Communications, conducts aircraft accident investigations in Ethiopia or involving Ethiopian aircraft. In France, the agency responsible for investigation of civilian air crashes is the Bureau d'Enquêtes et d'Analyses pour la Sécurité de l'Aviation Civile (BEA). Its purpose is to establish the circumstances and causes of the accident and to make recommendations for their future avoidance. In Germany, the agency for investigating air crashes is the Federal Bureau of Aircraft Accidents Investigation (BFU). It is an agency of the Federal Ministry of Transport and Digital Infrastructure. The focus of the BFU is to improve safety by determining the causes of accidents and serious incidents and making safety recommendations to prevent recurrence.
The discovery of actinium by Debierne was however questioned in 1971 and 2000, arguing that Debierne's publications in 1904 contradicted his earlier work of 1899–1900. This view instead credits the 1902 work of Friedrich Oskar Giesel, who discovered a radioactive element named emanium that behaved similarly to lanthanum. The name actinium comes from the Ancient Greek: ακτίς, ακτίνος (aktis, aktinos), meaning beam or ray. This metal was discovered not by its own radiation but by the radiation of the daughter products. Owing to the close similarity of actinium and lanthanum and low abundance, pure actinium could only be produced in 1950. The term actinide was probably introduced by Victor Goldschmidt in 1937. Protactinium was possibly isolated in 1900 by William Crookes. It was first identified in 1913, when Kasimir Fajans and Oswald Helmuth Göhring encountered the short-lived isotope 234mPa (half-life 1.17 minutes) during their studies of the 238U decay chain. They named the new element brevium (from Latin brevis meaning brief); the name was changed to protoactinium (from Greek πρῶτος + ἀκτίς meaning "first beam element") in 1918 when two groups of scientists, led by the Austrian Lise Meitner and Otto Hahn of Germany and Frederick Soddy and John Arnold Cranston of Great Britain, independently discovered the much longer-lived 231Pa. The name was shortened to protactinium in 1949. This element was little characterized until 1960, when Alfred Maddock and his co-workers in the U.K.
Lithium-ion Battery at the Encyclopædia Britannica. Degradation Mechanisms and Lifetime Prediction for Lithium-Ion Batteries, NREL, July 2015. Impact of Temperature Extremes on Large Format Li-ion Batteries for Vehicle Applications, NREL, March 2013.
Sources: en.wikipedia.org
=== Protein Structure === Using the PELE program of Biology WorkBench the protein sequence of FGFR1OP2 was analyzed, and FGFR1OP2 appears to be completely composed of alpha helices. No structural models for the Homo sapiens FGFR1OP2 protein could be found, but the Mus musculus FGFR1OP2 protein's structure can be seen below.
==== Dame Commander of the Order of the British Empire (DBE) ==== Civil Division Rachael Mary Dyche, . For political service. Deirdre Joan Hine, Chief Medical Officer, Welsh Office. For services to Medicine. Barbara Jean Lyon Mills, , Director of Public Prosecutions. Bridget Margaret Ogilvie, Director, Wellcome Trust. For services to Science. Diplomatic Service and Overseas List The Honourable Rosanna Wong Yick-ming, . For public and community service, Hong Kong.
== Early life and education == Bilawal Zardari was born at the Lady Dufferin Hospital in Karachi, Sindh, on 21 September 1988 to Benazir Bhutto, who served as the Prime Minister of Pakistan on two occasions, and her husband, Asif Ali Zardari, who is the incumbent President of Pakistan. He is the maternal grandson of former President and Prime Minister of Pakistan, Zulfikar Ali Bhutto, and his wife Nusrat Bhutto. His paternal grandfather, Hakim Ali Zardari, was a politician and a member of the National Assembly of Pakistan. From his mother's side, he is the nephew of politicians Murtaza Bhutto and Shahnawaz Bhutto, and from his father's side, his aunts are politicians Azra Peechoho and Faryal Talpur. Politician Ghinwa Bhutto is his aunt by marriage. Author Fatima Bhutto and San Francisco based artist Zulfikar Ali Bhutto Jr are his maternal cousins. He is of Sindhi and Kurdish descent on his maternal side and Baloch descent on his paternal side. For early education, Bhutto Zardari attended Karachi Grammar School and Froebel's International School in Islamabad before going into exile to Dubai in 1999 along with his mother. In Dubai, he attended the Rashid School For Boys. For further studies, he followed in the footsteps of both his mother and his grandfather and applied to Oxford University, where he was accepted to study Modern History and Politics at Christ Church, receiving his Bachelor of Arts degree in 2012 (later promoted to a Master of Arts by seniority).
Sports tournaments in Jammu and Kashmir are organised by both the Indian army and police, as well as mainstream political parties and the All Parties Hurriyat Conference. Sportspersons who represent India in tournaments face stigmatisation from separatists. Jammu and Kashmir has 18 stadiums, 23 training centres, three indoor sports complexes and 42 government-maintained playing fields. Srinagar is home to the Sher-i-Kashmir Stadium, a stadium where international cricket matches have been played. The Maulana Azad Stadium in Jammu is one of the home venues for the Jammu and Kashmir cricket team. The Bakshi Stadium in Srinagar, named after Bakshi Ghulam Mohammad, hosts football matches. Institutions such as the Jawahar Institute of Mountaineering and Winter Sports provides mountaineering, skiing and adventure courses. The Royal Springs Golf Course, Srinagar, located on the banks of Dal lake, is considered one of the best golf courses in India. Jammu and Kashmir was also host to the first Khelo India Winter Games, held in 2020 in Gulmarg. Jammu and Kashmir came first with the most gold medals at 26, followed by the Indian Army team with 8 gold medals. The second edition of the winter games were also held in Gulmarg in 2021, with Jammu and Kashmir coming first again.
Preventing DAMP release – proapoptotic therapies, platinums, ethyl pyruvate Neutralizing or blocking DAMPs extracellularly – anti-HMGB1, rasburicase, sRAGE, etc. Blocking the DAMP receptors or their signaling – RAGE small molecule antagonists, TLR4 antagonists, antibodies to DAMP-R DAMPs can be used as biomarkers for inflammatory diseases and potential therapeutic targets. For example, increased S100A8/A9 is associated with osteophyte progression in early human osteoarthritis, suggesting that S100 proteins can be used as biomarkers for the diagnosis of the progressive grade of osteoarthritis. Furthermore, DAMP can be a useful prognostic factor for cancer. This would improve patient classification, and a suitable therapy would be given to patients by diagnosing with DAMPs. The regulation of DAMP signaling can be a potential therapeutic target to reduce inflammation and treat diseases. For example, administration of neutralizing HMGB1 antibodies or truncated HMGB1-derived A-box protein ameliorated arthritis in collagen-induced arthritis rodent models. Clinical trials with HSP inhibitors have also been reported. For nonsmall-cell lung cancer, HSP27, HSP70, and HSP90 inhibitors are under investigation in clinical trials. In addition, treatment with dnaJP1, which is a synthetic peptide derived from DnaJ (HSP40), had a curative effect in rheumatoid arthritis patients without critical side effects. Taken together, DAMPs can be useful therapeutic targets for various human diseases, including cancer and autoimmune diseases.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.